Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. |
SAN FRANCISCO – Compared with as needed treatment, monthly intravitreal injection of ranibizumab was associated with a statistically significant gain in vision in patients with radiation retinopathy-related macular edema (RR-CME), according to data presented at the 2019 American Academy of Ophthalmology Meeting in San Francisco, CA.
The phase 2, randomized, multicenter, clinical study assessed the tolerability and efficacy of ranibizumab treatment administered in patients with RR-CME either monthly with or without peripheral targeted photocoagulation or monthly for 3 months followed by as needed treatment with peripheral targeted photocoagulation over 48 weeks; from week 52 to week 101, patients were then assigned to a treat and extend protocol for intravitreal ranibizumab treatment. The primary end point of the study was mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity at 48 weeks and 104 weeks from Day 0.
Results showed that compared with the as-needed group, those who received monthly injections had a statistically significant gain in vision at Year 1. However, no significant gain in vision was observed at Year 2 in any of the treatment arms when compared to one another (P=.379) or to baseline (P=.34). Treatment with ranibizumab was associated with significant improvements in central macular thickness from baseline to Year 1 which then stabilized at Year 2 (P=.94), according to the researchers.
“By year 2, some of visual gains had been lost, and mean vision was essentially stable from baseline in all 3 cohorts. However, almost no patients had 20/400 or worse vision and almost one-third of patients had 40/40 or better vision, a significant improvement over historical controls,” the researchers concluded.
Reference
Schefler, A, et al. Randomized Trial of Monthly vs. PRN Intravitreal Injection of Ranibizumab With and Without PRN Targeted PRP for Radiation-Induced Macular Edema: RRR 2-Year Anatomic Outcomes. Poster number: PO283. The American Academy of Ophthalmology Meeting; October 12-15 2019.
